(Q65351997)

English

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

clinical trial

In more languages
default for all languages
No label defined

No description defined

Statements

CIMPASI-2 (English)
0 references
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis (English)
0 references
0 references
0 references
0 references
15 December 2014
0 references
5 January 2016
0 references
227
0 references
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit